abstract: Pyridoxine (Vitamin B6) to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect

CONCLUSIONS:

Administration of pyridoxine (Vitamin B6) , at concentrations extending across possible therapeutic plasma levels in humans, does not antagonise OHP (Oxaliplatin) antitumour effects in a range of relevant tumour cell lines.

This study provides a foundation for clinical studies to test whether pyridoxine can minimise OHP-related neurotoxicity, and clinicians can be confident that pyridoxine is very unlikely to reverse the antitumour effects of OHP, as seems to be the case with Ca/Mg infusions.

This could prove to be a cost-effective way to minimise OHP-related neurotoxicity, allowing more effective less toxic treatment and better outcomes in patients.

A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gyne

Blogger's Note: in the absence of full access to the article, this conclusion 'needs more research'


"CONCLUSIONS:: Pyridoxine as administered in the current study did not prevent HFS in patients who received PLD. It is possible that QOL is not compromised in patients with HFS because they may have increased social well being while coping with their disease."